Seeking Alpha

Ipsen starts resupply of Increlex

  • Ipsen's (IPSEY -1%) U.S. affiliate Ipsen Biopharmaceuticals says one batch of its orphan drug Increlex (mecasermin [rDNA origin] injection) will be available in the U.S. on June 2. Additional lots will be available over the coming months.
  • Increlex is used to treat children afflicted with a form of growth failure known as severe primary IGF-1 deficiency which can cause permanent short stature.
  • The supply interruption began almost a year ago due to manufacturing problems at Lonza Biologics, the maker of Increlex's active ingredient.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: